Indivior PLC INVVY
21.85 0.00 (+0.00%)
Jun 9, 2023, 10:23 AM EDT
21.85 Day range 21.85
14.76 52-week range 75.65
News
fool.com Why Indivior Pharmaceuticals Stock Topped the Market Today The peer is Supernus Pharmaceuticals. The combined business will bear the Supernus name and stock ticker under the terms of a deal announced in August.
globenewswire.com Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader ROCKVILLE, Md., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN)1 today announced the successful completion of the merger between Supernus Pharmaceuticals, Inc. and Indivior…
globenewswire.com Indivior Reports Third Quarter 2026 Financial Results Q3'26 Total Net Revenue of $ 356 Million, Up 13% YoY Record Quarterly Total SUBLOCADE® Net Revenue of $ 267 Million in Q3'26, Up 22% YoY Record Quarterly Net Income of $ 137 Million and Record…
globenewswire.com Indivior to Report Third Quarter 2026 Financial Results RICHMOND, Va., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its third quarter 2026 financial results on Thursday, October 29,…
globenewswire.com Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 25, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company developing novel small…
globenewswire.com Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend RICHMOND, Va., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) (“Indivior”) today announced that its Board of Directors declared a special cash dividend (the "Special…
businesswire.com INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) and Supernus Pharmaceuticals, Inc. Upon closing…
zacks.com Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.
defenseworld.net Indivior (OTCMKTS:INVVY) Share Price Passes Below Two Hundred Day Moving Average – Should You Sell? Shares of Indivior PLC (OTCMKTS:INVVY - Get Free Report) crossed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $21.85 and traded as low as…
benzinga.com Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Indivior Pharmaceuticals Inc. (NASDAQ:INDV) on Monday agreed to unite through a tax-free all-stock merger of equals, forming a central nervous system…
businesswire.com INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) and Supernus Pharmaceuticals, Inc. Upon closing…
zacks.com Indivior Pharmaceuticals Inc. (INDV) Q2 Earnings and Revenues Beat Estimates Indivior Pharmaceuticals Inc. (INDV) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $0.51 per share a year…
reuters.com Supernus, Indivior merge to strengthen neuroscience drug portfolio Supernus Pharmaceuticals and Indivior Pharmaceuticals said on Monday they had agreed to an all-stock merger that would create a company with about $2.2 billion in annual revenue and a portfolio of…
globenewswire.com Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance • Q2'26 Total Net Revenue of $ 343 Million, Up 14% YoY • Record Quarterly Total SUBLOCADE® Net Revenue of $ 253 Million in Q2'26, Up 21% YoY • Record Quarterly GAAP Net Income of $122 Million and…
globenewswire.com Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale ROCKVILLE, Md. and RICHMOND, Va., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that they have…
globenewswire.com Indivior to Report Second Quarter 2026 Financial Results and Host Webcast RICHMOND, Va., July 23, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its second quarter 2026 financial results on Tuesday, August 4,…
zacks.com Indivior Pharmaceuticals Inc. (INDV) is on the Move, Here's Why the Trend Could be Sustainable Indivior Pharmaceuticals Inc. (INDV) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks…
zacks.com Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
zacks.com Is Indivior Stock a Buy After Higher 2026 Guidance? Indivior raised 2026 guidance after strong Q1 results, but investors are watching whether Sublocade growth and margin gains can sustain momentum.
zacks.com Bears are Losing Control Over Indivior Pharmaceuticals Inc. (INDV), Here's Why It's a 'Buy' Now Indivior Pharmaceuticals Inc. (INDV) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate…
benzinga.com Earnings Scheduled For July 30, 2020 Companies Reporting Before The Bell • Mastercard Inc. (NYSE:MA) is expected to report quarterly earnings at $1.16 per share on revenue of $3.23 billion. • Moody's Inc. (NYSE:MCO) is expected to…